Patents by Inventor Michael Michaelides
Michael Michaelides has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399340Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: October 12, 2022Publication date: December 14, 2023Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
-
Patent number: 11811613Abstract: Systems, methods, and computer-readable media for identifying a spanning tree loop in a network environment. Spanning tree loop indicators occurring in a network environment that utilizes a spanning tree protocol are identified. The spanning tree loop indicators are correlated to identify correlated spanning tree loop indicators within the network environment. A potential spanning tree loop is recognized from a plurality of the correlated spanning tree loop indicators based on indicator types of the correlated spanning tree loop indicators. The potential spanning tree loop is remedied in the network environment in response to recognizing the potential spanning tree loop in the network environment.Type: GrantFiled: November 14, 2022Date of Patent: November 7, 2023Assignee: Cisco Technology, Inc.Inventors: Zachariah Cherian, Samer Salam, Ajay Madhavan, Tarunesh Ahuja, Michael Michaelides, Smruti Dilip Lele
-
Patent number: 11739063Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.Type: GrantFiled: February 6, 2019Date of Patent: August 29, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Johns Hopkins UniversityInventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
-
Publication number: 20230075769Abstract: Systems, methods, and computer-readable media for identifying a spanning tree loop in a network environment. Spanning tree loop indicators occurring in a network environment that utilizes a spanning tree protocol are identified. The spanning tree loop indicators are correlated to identify correlated spanning tree loop indicators within the network environment. A potential spanning tree loop is recognized from a plurality of the correlated spanning tree loop indicators based on indicator types of the correlated spanning tree loop indicators. The potential spanning tree loop is remedied in the network environment in response to recognizing the potential spanning tree loop in the network environment.Type: ApplicationFiled: November 14, 2022Publication date: March 9, 2023Inventors: Zachariah Cherian, Samer Salam, Ajay Madhavan, Tarunesh Ahuja, Michael Michaelides, Smruti Dilip Lele
-
Patent number: 11516086Abstract: Systems, methods, and computer-readable media for identifying a spanning tree loop in a network environment. Spanning tree loop indicators occurring in a network environment that utilizes a spanning tree protocol are identified. The spanning tree loop indicators are correlated to identify correlated spanning tree loop indicators within the network environment. A potential spanning tree loop is recognized from a plurality of the correlated spanning tree loop indicators based on indicator types of the correlated spanning tree loop indicators. The potential spanning tree loop is remedied in the network environment in response to recognizing the potential spanning tree loop in the network environment.Type: GrantFiled: September 4, 2019Date of Patent: November 29, 2022Assignee: Cisco Technology, Inc.Inventors: Zachariah Cherian, Samer Salam, Ajay Madhavan, Tarunesh Ahuja, Michael Michaelides, Smruti Dilip Lele
-
Patent number: 11394604Abstract: The present technology addresses a need in the art for a closed-loop automation system of a managed network that detects and fixes an issue in the managed network with minimal to no human intervention. The closed-loop automation system employs a domain-independent semantic machine reasoning engine as an underlying engine. After detecting the issue in the managed network, the system searches through a knowledge base to find a match for the detected issue. The knowledge base includes previously collected knowledge from subject matter experts and maintenance teams. The system then proposes a remedial action to a user of the managed network for approval. After approval by the user, the system implements the remedial action.Type: GrantFiled: September 10, 2020Date of Patent: July 19, 2022Assignee: CISCO TECHNOLOGY, INC.Inventors: Ammar Rayes, Arun Mammen Thomas, Samer Salam, Michael Michaelides, Arabinda Samantaray, Madhavan Kasthurirangan, Ram Prasanna Govind Krishnan, Asad Ghayas Ahmed, Thuan Quang Truong, Ajay Madhavan, Xixi Luo, Samhith Venkatesh
-
Publication number: 20220078072Abstract: The present technology addresses a need in the art for a closed-loop automation system of a managed network that detects and fixes an issue in the managed network with minimal to no human intervention. The closed-loop automation system employs a domain-independent semantic machine reasoning engine as an underlying engine. After detecting the issue in the managed network, the system searches through a knowledge base to find a match for the detected issue. The knowledge base includes previously collected knowledge from subject matter experts and maintenance teams. The system then proposes a remedial action to a user of the managed network for approval. After approval by the user, the system implements the remedial action.Type: ApplicationFiled: September 10, 2020Publication date: March 10, 2022Inventors: Ammar Rayes, Arun Mammen Thomas, Samer Salam, Michael Michaelides, Arabinda Samantaray, Madhavan Kasthurirangan, Ram Prasanna Govind Krishnan, Asad Ghayas Ahmed, Thuan Quang Truong, Ajay Madhavan, Xixi Luo, Samhith Venkatesh
-
Publication number: 20200399228Abstract: Disclosed is a compound of formula (I) in which R1, R2, and R3 are as described herein. Also provided are pharmaceutical compositions comprising the compound of formula (I) and methods of using the compound of formula (I), including a method of treating a disease or disorder and a method for effectuating a G-protein coupled receptor (GPCR)-mediated response in a subject.Type: ApplicationFiled: February 6, 2019Publication date: December 24, 2020Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, The Johns Hopkins UniversityInventors: Jordi Bonaventura, Juan Luis Gomez, Andrew Horti, Feng Hu, Michael Michaelides, Martin Pomper, Marta Sanchez-Soto
-
Publication number: 20200239494Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: August 15, 2018Publication date: July 30, 2020Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Michael Michaelides
-
Patent number: 10093624Abstract: Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are isoindoline carboxamide, dihydropyrrolopyridine carboxamide, and dihydropyrrolopyrimidine carboxamide compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.Type: GrantFiled: October 12, 2015Date of Patent: October 9, 2018Assignee: AbbVie Inc.Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
-
Publication number: 20180093956Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).Type: ApplicationFiled: February 6, 2015Publication date: April 5, 2018Inventors: Yujia Dai, Michael Michaelides
-
Patent number: 9796708Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).Type: GrantFiled: March 13, 2014Date of Patent: October 24, 2017Assignee: AbbVie Inc.Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iguturi, Madhu Babu Dabbeeru
-
Publication number: 20170135994Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: May 18, 2017Applicant: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Publication number: 20160184282Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: June 30, 2016Applicant: AbbVie Inc.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Publication number: 20160184281Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: October 8, 2015Publication date: June 30, 2016Applicant: ABBVIE INC.Inventors: Richard F. Clark, Bryan Sorensen, Augustine T. Osuma, Robin Frey, Kenton Longenecker, George Doherty, Michael L. Curtin, Michael Michaelides, Ramzi Sweis, Marina Pliushchev, Andrew Judd, Todd Hansen, Howard R. Heyman
-
Patent number: 9302989Abstract: Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of using the compounds to treat diseases during which NAMPT is expressed, e.g., cancer, metabolic disorders, and inflammatory disorders. Disclosed are 1,3-dihydro-2H-isoindole compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of using the compounds to treat diseases during which ROCK is expressed, e.g., cancer, cardiovascular disorders, and inflammatory disorders.Type: GrantFiled: November 11, 2011Date of Patent: April 5, 2016Assignee: AbbVie Inc.Inventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev
-
Publication number: 20160060257Abstract: Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).Type: ApplicationFiled: March 13, 2014Publication date: March 3, 2016Applicant: ABBVIE INC.Inventors: Yunsong Tong, Milan Bruncko, Richard F. Clark, Michael Curtin, Alan S. Florjancic, Robin R. Frey, Jianchun Gong, Todd M. Hansen, Zhiqin Ji, Chunqiu Lai, Anthony Mastracchio, Michael Michaelides, Juliem Miyashiro, Roberto M. Risi, Xiaohong Song, Zhi-fu Tao, Keith W. Woods, Guidong Zhu, Thomas Penning, Andrew Souers, Rajeev Goswami, Omprakash Reddy Iquturi, Madhu Babu Dabbeeru
-
Publication number: 20160031880Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.Type: ApplicationFiled: October 12, 2015Publication date: February 4, 2016Applicant: ABBVIE INC.Inventors: Rick F. Clark, Michael L. Curtain, Todd M. Hansen, Howard R. Heyman, Helmut Mack, Michael Michaelides, Marina A. Pliushchev, Omar J. Shah, Bryan K. Sorensen, Ramzi Sweis, Chris Tse, Anil Vasudevan, Kevin R. Woller
-
Publication number: 20120122842Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed. Disclosed are compounds which inhibit the activity of ROCK, compositions containing the compounds and methods of treating diseases during which ROCK is expressed.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: Abbott LaboratoriesInventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Richard F. Clark, Kevin R. Woller, Omar J. Shah, Michael Michaelides, Chris Tse, Anil Vasudevan, Helmut Mack, Todd M. Hansen, Ramzi Sweis, Marina A. Pliushchev
-
Publication number: 20120122924Abstract: Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: ABBOTT LABORATORIESInventors: Michael L. Curtin, Bryan K. Sorensen, Howard R. Heyman, Rick F. Clark, Michael Michaelides, Chris Tse